Cargando…
Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients
INTRODUCTION: Tumour burden is a prognostic biomarker in metastatic melanoma. However, tumour burden is difficult to measure and there are currently no reliable surrogate biomarkers to easily and reliably determine it. The aim of this study was to assess the potential of plasma total cell free DNA a...
Autores principales: | Valpione, S., Gremel, G., Mundra, P., Middlehurst, P., Galvani, E., Girotti, M.R., Lee, R.J., Garner, G., Dhomen, N., Lorigan, P.C., Marais, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769519/ https://www.ncbi.nlm.nih.gov/pubmed/29175734 http://dx.doi.org/10.1016/j.ejca.2017.10.029 |
Ejemplares similares
-
Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA
por: Gremel, G., et al.
Publicado: (2016) -
Immune-awakening revealed by peripheral T cell dynamics after one
cycle of immunotherapy
por: Valpione, Sara, et al.
Publicado: (2020) -
Methylation pattern of caveolin-1 in prostate cancer as potential cfDNA biomarker
por: Škara, Lucija, et al.
Publicado: (2023) -
Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer
por: Thakur, Kavita, et al.
Publicado: (2021) -
Impact of Circulating Cell-Free DNA (cfDNA) as a Biomarker of the Development and Evolution of Periodontitis
por: Viglianisi, Gaia, et al.
Publicado: (2023)